Generate Biomedicines, Inc. Common Stock (GENB) is a publicly traded the market company. As of July 5, 2026, GENB trades at $17.41 with a market cap of $2.23B and a P/E ratio of -16.27. GENB moved +5.39% today. Year to date, GENB is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $11.00 to $18.18. Analyst consensus is strong buy with an average price target of $25.40. Rallies surfaces GENB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Generate Biomedicines' Andover Campus Hits 100% Occupancy with 128,000 Sq Ft AdvanCell Lease: Innovation Park in Andover now stands 100% leased after AdvanCell signed a 128,000 sq ft long-term lease, joining Generate Biomedicines in the 340,000 sq ft campus featuring cGMP facilities and amenities. The fully occupied park secures dedicated manufacturing and infrastructure, enhancing operational stability for Generate Biomedicines.
| Metric | Value |
|---|---|
| Price | $17.41 |
| Market Cap | $2.23B |
| P/E Ratio | -16.27 |
| EPS | $-1.07 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.18 |
| 52-Week Low | $11.00 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $7.22M |
| Net Income | $-61.71M |
| Gross Margin | 0.00% |
5 analysts cover GENB: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.40.